A new study found that epilepsy patients may benefit from a one-a-day medication instead of the traditional two-a-day drug, which is currently used. The findings are still in their early phase, and the researchers compared the effectiveness of eslicarbazepine acetate (Aptiom), which is a one-a-day drug, to carbamazepine (Tegretol, Carbatrol), a two-a-day drug, in over 800 patients newly diagnosed with partial seizures. The researchers found that after six months, 71 percent of one-a-day users and 76 percent of two-a-day users were seizure-free.
Dr. Sean Hwang, an attending neurologist at Northwell Health’s Comprehensive Epilepsy Care Center added, “The study shows eslicarbazepine to be as effective as the older, more tried-and-true drug, carbamazepine, from which it is derived. A longer-acting compound, with once daily dosing, may make it easier for patients to comply with their medication regimen, avoid missed doses, and reduce their risk for breakthrough seizures.”